Santen Pharmaceutical has entered into a licensing agreement with Cloudbreak Pharma to develop, manufacture, and commercialise CBT-001, a topical pterygium treatment, for certain territories.
Genmab has assumed the complete ownership of the acasunlimab development programme, including its continued development and potential commercialisation, contingent on approval.
Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.
Lynch Regenerative Medicine (LRM) has closed its Series A financing round for the development and commercialisation of advanced skin rejuvenation and regeneration solutions.
MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.
Singapore-based Juniper Biologics has secured the distribution rights for Caris Life Sciences' advanced solid tumour molecular profiling services in the Middle East and Africa (MEA).
The Department of Health – Abu Dhabi (DoH) and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) have signed a second Memorandum of Understanding (MoU) to broaden their collaboration in translational research.
Telix Pharmaceuticals has completed Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) for TLX250-CDx (Zircaix), a radiodiagnostic agent for identifying clear cell renal cell carcinoma (ccRCC) in kidney cancer patients.
FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.
PharmaLogic, a contract development and manufacturing organization (CDMO) and provider of radiopharmacy solutions, has announced the launch of its new radiopharmaceutical manufacturing and research facility at the Bronx in New York city, US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.